Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC + tumors respond to PD1/PD-L1 blockade therapy

ConclusionOur findings provide the proof-of-concept rationale and previously undiscovered mechanisms for co-targeting sMIC to enable and enhance the response to PD1/PD-L1 blockade therapy in sMIC+ cancer patients.

http://link.springer.com/10.1186/s40425-019-0693-y

Source: Journal for Immunotherapy of Cancer - August 25, 2019 Category: Cancer & Oncology Source Type: research

More News: Cancer | Cancer & Oncology | Immunotherapy